Cipla Ltd

(CIPLA)

Cipla Recalls Lanthanum Carbonate Tablets in US - 21 Nov, 2024

Cipla's US subsidiary is recalling 1,875 boxes of Lanthanum Carbonate chewable tablets due to complaints of broken tablets, as reported by the USFDA.

Cipla Recalls Lanthanum Carbonate Due to Defects - 20 Nov, 2024

Cipla is recalling over 1,800 boxes of Lanthanum Carbonate chewable tablets in the US due to reports of broken tablets. The recall is classified as Class II, indicating potential temporary health risks.

Cipla Allocates Equity Shares Under ESOS - 15 Nov, 2024

Cipla has allotted 17,064 equity shares under its Employee Stock Option Scheme 2013-A and Stock Appreciation Rights Scheme 2021, increasing its paid-up share capital to Rs 1,61,52,25,016.

Cipla Faces USFDA Observations at Bengaluru Facility - 14 Nov, 2024

Cipla's Bengaluru manufacturing facility received eight observations from the USFDA following an inspection. The company is committed to addressing these observations promptly.

Cipla Faces FDA Observations After Inspection - 13 Nov, 2024

Cipla Ltd announced it received eight observations from the US FDA following an inspection of its Bengaluru facility. The company is committed to addressing these observations promptly. Despite a strong quarterly profit report, shares fell 1.3% on the news.

Cipla Confident in Growth Despite Temporary Challenges - 11 Nov, 2024

Cipla's CEO Umang Vohra expresses confidence in the company's growth trajectory, citing opportunities from the biosecurity act and government health programs. Despite temporary supply disruptions and a high base effect, Cipla anticipates 10-12% growth in India, supported by a robust product pipeline and FDA compliance efforts.

Cipla Targets Growth Amid Supply Challenges - 05 Nov, 2024

Cipla is addressing slow seasonal growth in its One India business while managing supply issues with generic Lanreotide. The company anticipates recovery in Q4 FY25. Analysts maintain an ACCUMULATE rating with a target price of INR 1,680/share, reflecting confidence in future growth.

Cipla Stock Rises on Positive FDA Goa Facility News - 04 Nov, 2024

Cipla's stock surged following the USFDA's VAI classification of its Goa facility, enhancing prospects for drug launches like gAbraxane. Brokerages upgraded ratings, citing growth potential despite existing challenges. The stock closed up 1.63% on November 4, 2024.

Cipla Shares Surge After USFDA VAI Status - 31 Oct, 2024

Cipla shares jumped nearly 10% following the USFDA's Voluntary Action Indicated (VAI) status for its Goa facility, alleviating regulatory concerns and paving the way for new product launches, including a generic version of Abraxane. The stock's positive momentum reflects market confidence in Cipla's growth potential in the oncology segment.

Cipla Faces Challenges Despite Q2 Profit Growth - 30 Oct, 2024

Cipla reported a 15% increase in net profit for Q2, but faced challenges including weak domestic sales and supply issues. Analysts cut target prices, leading to a decline in share price. UBS and other brokerages express concerns over future growth prospects.

Cipla Reports Strong Q2 Results Amid Challenges - 29 Oct, 2024

Cipla's Q2 results show a 17% net profit increase to ₹1,303 crore, despite regulatory delays affecting key drug launches. Promoter Kamil Hamied returns to the board.

Cipla Q2 Preview Indicates Modest Growth - 28 Oct, 2024

Analysts anticipate Cipla's Q2FY25 results to show low single-digit growth in sales and profit, with net profit expected at Rs 1,174 crore, a 1.55% YoY increase. Revenue may rise 4.1% YoY to Rs 6,957 crore, but margins could be impacted by lower US sales. Overall, a 3% YoY growth in sales is projected.

Cipla Completes Acquisition of Stake in Cipla Jiangsu - 25 Oct, 2024

Cipla has successfully completed the acquisition of an additional 6.9% equity interest in Cipla Jiangsu Pharmaceuticals, making it a wholly owned step-down subsidiary as of October 25, 2024.